Drug Profile

KUR 101

Alternative Names: KUR-101

Latest Information Update: 27 Dec 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Columbia University
Developer ATAI Life Sciences; Kures
Class Alkaloids; Analgesics; Drug withdrawal therapies; Small molecules
Mechanism of Action Opioid receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Acute pain; Opioid-related disorders

Most Recent Events

23 Dec 2022 Safety and efficacy data from a phase I trial in Acute pain released by ATAI Life sciences
14 Oct 2022 Phase-I clinical trials in Opioid-related disorders in USA (PO) ,prior to October 2022 (ATAI Life sciences pipeline, October 2022)
14 Oct 2022 Safety and efficacy data from a phase I trial in Acute pain released by ATAI Life sciences

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com